Michael Allen Dobbins

Title: Michael Allen Dobbins: Innovator in Pharmaceutical Compositions

Introduction

Michael Allen Dobbins is a notable inventor based in Lebanon, Indiana, with a focus on pharmaceutical innovations. He holds four patents that contribute significantly to the field of drug formulation and stability. His work primarily revolves around improving the chemical stability of pharmaceutical compositions, particularly those involving polypeptides.

Latest Patents

Dobbins' latest patents include groundbreaking inventions such as "Polypeptide compositions with improved stability." This invention provides methods to enhance the chemical stability of aqueous, parenteral pharmaceutical compositions that contain a polypeptide and glycerin. The patent identifies reactive aldehydes present in commercial glycerins and offers solutions for reducing their impact. It also presents convenient methods for assaying reactive aldehydes in glycerin, demonstrating a strong correlation between these aldehydes and the stability of polypeptide compositions. Another significant patent is for "Stable insulin formulations," which describes a monomeric insulin analog formulation that is stabilized against aggregation. This formulation utilizes buffering agents like TRIS or arginine, making it particularly useful for diabetes treatment, especially in continuous infusion systems.

Career Highlights

Dobbins is associated with Eli Lilly and Company, a leading pharmaceutical firm known for its innovative contributions to healthcare. His work at Eli Lilly has allowed him to focus on developing stable formulations that are crucial for effective diabetes management and other therapeutic applications.

Collaborations

Throughout his career, Dobbins has collaborated with esteemed colleagues, including Michael Rosario DeFelippis and Bruce H Frank. These collaborations have likely enriched his research and contributed to the successful development of his patented inventions.

Conclusion

Michael Allen Dobbins stands out as an influential inventor in the pharmaceutical industry, with a strong emphasis on enhancing the stability of drug formulations. His contributions are vital for advancing treatment options in diabetes and other medical conditions.